Author

Carmela Gnerre

Idorsia Pharmaceuticals Ltd (Switzerland)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Agnes KnopfiD· 1 shared Alexandra HardyiD· 1 shared Alexandre GrimaldiiD· 1 shared Andrew J. PierceiD· 1 shared Anna ThalleriD· 1 shared Caroline HoffmanniD· 1 shared Eva Huehn· 1 shared Floriane MontanariiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Agnes KnopfORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

OKN4395, a first-in-class EP2/EP4/DP1 triple antagonist reprograms prostanoid-driven immunosuppression to restore antitumor immunity

Maximilien Grandclaudon, Morgane Boulch, Anna Thaller, Jonathan Sabio-Ortiz, Alexandre Grimaldi, Marie Goxe, Agnes Knopf, Marie V. Daugan, Eva Huehn, Carmela Gnerre, Sébastien Jeay, Monica Faronato, Haithem Dakhli, Silvia Lopez‐Lastra, Alexandra Hardy, , Andrew J. Pierce

OKN4395, a triple EP2/EP4/DP1 antagonist, restores antitumor immunity by reversing prostanoid-driven immunosuppression and synergizes with anti-PD1 therapy.

bioRxiv · Feb 10, 2026 · PreprintPharmacology & Toxicology